The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1741
November 10, 2025
View Complete Issue         Table of Contents 2019 
Aceclidine (Vizz) for Presbyopia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Aceclidine (Vizz) for Presbyopia
November 10, 2025 (Issue: 1741)
The FDA has approved Vizz (Lenz Therapeutics), a 1.44% ophthalmic solution of the cholinergic agonist aceclidine, for treatment of presbyopia in adults. Aceclidine has been available in the EU for years for treatment of open-angle...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Aceclidine (Vizz) for Presbyopia
Article code: 1741a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.